CoChat

A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease

Lee, Daniel, Clark, Emily D., Antonsdottir, Inga M., Porsteinsson, Anton P. · 2023 · Expert Opinion on Pharmacotherapy

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's Disease (AD) are associated with negative outcomes for patients and their care partners. Agitation is a common and distressing NPS, without safe and effective treatments. Nonpharmacological interventions are first line treatment, but not effective or appropriate for every patient. Current pharmacological treatments of agitation in AD include off-label use of antipsychotics, sedative/hypnotics, anxiolytics, mood-stabilizing anticonvulsants, acetylcholinesterase inhibitors, NMDA receptor antagonists, and antidepressants. Despite prevalent use, efficacy and safety concerns remain. AREAS COVERED: Better understanding of neurobiological mechanisms of agitation have fueled recent clinical trials. This article is an update to our 2017 review. Comprehensive search of ClinicalTrials.gov was completed from January 2017 to February 2023 using the search terms "Alzheimer's Disease" and "Agitation". Subsequent scoping review was completed in PubMed and Google Scholar. Several agents were identified, including: brexpiprazole, cannabinoids, dexmedetomidine, dextromethorphan, escitalopram, masupirdine, and prazosin. EXPERT OPINION: Clinical trials utilize both novel and repurposed agents for agitation in AD. With increasing understanding of the neurobiological mechanisms that fuel development of agitation in AD, use of enahanced trial design and conduct, advanced statistical approaches, and accelerated pathways for regulatory approval, we advance closer to safe and efficacious treatment options for agitation in AD.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2023.2195539

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 15

  1. Patterson C., 2018, An analysis of prevalence, incidence, cost and trends.
  2. Otsuka Pharmaceutical Co. Otsuka Pharmaceutical and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole [Press Release]. Otsuka Pharmaceutical Co., H. Lundbeck A/S; 2022 [updated June 27]. Available from: https://www.otsuka.co.jp/en/company/newsreleases/2022/20220627_1.html
  3. Lundbeck A/S H. Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer’s Association International Conference [Press Release]. 2022 [updated August 4]. Available from: https://newsroom.lundbeckus.com/news-release/2022/otsuka-pharmaceutical-and-lundbeck-present-positive-results
  4. Lundbeck A/S H. Otsuka Pharmaceutical and Lundbeck Present Positive Data from Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms of Agitation in Patients with Alzheimer’s Dementia at the 2022 Clinical Trials for Alzheimer’s Disease Congress [Press Release]. 2022 [updated December 2]. Available from: https://newsroom.lundbeckus.com/news-release/2022/otsuka-pharmaceutical-and-lundbeck-present-positive-data-from-mu
  5. Otsuka Pharmaceutical Co. Otsuka and Lundbeck Announce Decision to Continue Phase III Clinical Trial Evaluating Brexpiprazole for Treatment of Agitation in Patients with Alzheimer’s-type Dementia [Press Release]. 2021 [updated April 13]. Available from: https://www.otsuka-us.com/node/1286
  6. Otsuka Pharmaceutical Co. Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia [Press Release]. Otsuka Pharmaceutical Co., Ltd., Lundbeck A/S; 2023 [updated January 7; cited 2023 February 24]. Available from: https://www.otsuka-us.com/news/otsuka-and-lundbeck-announce-fda-acceptance-and-priority-review-snda-brexpiprazole-treatment
  7. Sunnybrook Health Sciences Centre AsDDF, Weston Brain Institute, 2021, Nabilone for Agitation Blinded Intervention Trial
  8. BioXcel Therapeutics. BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia [Press Release]. 2021 [updated March 15]. Available from: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-receives-fda-breakthrough-therapy
  9. BioXcel Therapeutics. BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease [Press Release]. 2021 [updated January 5]. Available from: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-bxcl501-met-primary-and-all
  10. Axsome Therapeutics. Axsome Therapeutics receives fda breakthrough therapy designation for axs-05 for the treatment of alzheimer’s disease agitation [Press Release]. 2020 [updated June 26]. Available from: https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-receives-fda-breakthrough-therapy-0
  11. Avanir Pharmaceuticals. Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer’s Dementia [Press Release]. 2019 [updated March 24]. Available from: https://www.avanir.com/press/avanir-pharmaceuticals-inc-reports-phase-3-data-evaluating-investigational-avp-786-treatment
  12. Axsome Therapeutics. Axsome Therapeutics announces axs-05 achieves primary endpoint in the accord phase 3 trial in alzheimer’s disease agitation [Press Release]. 2022 [updated November 28]. Available from: https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-3
  13. 10.1176/jnp.16.3.261 · doi:10.1176/jnp.16.3.261 · Paper page
  14. Alzheimer’s Disease Cooperative Study NIoA, 2018, Prazosin for Agitation in Alzheimer’s Disease
  15. Peskind ER, 15th Conference Clinical Trials Alzheimer’s Disease (CTAD)

Cited by

See all 30

Metadata

Authors
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P.
Affiliations
  • University of Rochester Medicine (US)
  • Johns Hopkins University (US)
Corresponding author
Porsteinsson, Anton P.
Venue
Expert Opinion on Pharmacotherapy
Published
2023-03-28
Volume
24
Issue
6
Pages
691-703
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W4360602811
Cited by
28
References
55
Citations by year
2026: 3 · 2025: 9 · 2024: 10 · 2023: 1
FWCI
4.68
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, agitation, neuropsychiatric symptoms, pharmacotherapy, non-pharmacological treatment, antipsychotic drugs, sedative-hypnotic drugs, anxiolytics, acetylcholinesterase inhibitors, NMDA receptor antagonists, antidepressants, brexpiprazole, cannabinoids, dexmedetomidine, dextromethorphan, escitalopram, prazosin, drug repurposing, neurobiological mechanisms, clinical trials
MeSH terms
Acetylcholinesterase, Alzheimer Disease, Antidepressive Agents, Humans, Psychomotor Agitation, Antipsychotic Agents, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/14656566.2023.2195539
The paper
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023). A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2023.2195539

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.